Login to Your Account

Other News To Note

Wednesday, October 3, 2012

• Cell Therapeutics Inc. (CTI), of Seattle, said the FDA granted orphan drug designation to Opaxio (paclitaxel poliglumex), formerly known as Xyotax, in glioblastoma multiforme (GBM) based on preliminary activity seen in Phase II results of Opaxio when added to standard therapy (temozolamide, or TMZ, plus radiation). The study showed encouraging progression-free and overall survival among patients with GBM, including those whose tumors expressed unmethylated MGMT.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription